AbbVie (ABBV) Cash from Financing Activities (2012 - 2026)

AbbVie (ABBV) has reported Cash from Financing Activities for 15 consecutive years, with -$5.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 86.49% year-over-year to -$5.1 billion in Q2 2026; TTM through Jun 2026 was -$12.9 billion, a 7.27% increase from a year earlier, with the FY2025 full-year figure at -$12.7 billion, down 144.18% from the prior year.
• Cash from Financing Activities was -$5.1 billion for Q2 2026 at AbbVie, down from $919.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $10.8 billion in Q1 2024 and troughed at -$9.6 billion in Q4 2022.
• A 5-year average of -$3.6 billion and a median of -$4.3 billion in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 119.66% in 2022 and soared 274.73% in 2024, its largest moves.
• Over 5 years, Cash from Financing Activities stood at -$9.6 billion in 2022, then surged by 53.82% to -$4.4 billion in 2023, then plunged by 54.21% to -$6.9 billion in 2024, then surged by 39.28% to -$4.2 billion in 2025, then declined by 21.32% to -$5.1 billion in 2026.
• The last three Cash from Financing Activities figures came in at -$5.1 billion (Q2 2026), $919.0 million (Q1 2026), and -$4.2 billion (Q4 2025), per Business Quant data.